Catalog Products » IL-5, His, Cynomolgus
Manual
Manual
COAs

IL-5, His, Cynomolgus

IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA).
$390.00
Z04845-100

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
His IL-5 (Ile20-Ser134)
Accession # A0A2K5U1E7
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 14.25 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 20-25 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

IL-5, His, Cynomolgus

Immobilized IL-5, His, Cynomolgus, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Human IL-5 R alpha, hFc Tag with the EC50 of 18.9ng/ml determined by ELISA. »

IL-5, His, Cynomolgus

The purity of IL-5, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »

IL-5, His, Cynomolgus

IL-5, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA).
Synonyms Interleukin-5; IL-5; T-cell replacing factor; TRF; EDF
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.